DUBLIN – After 18 months in stealth mode, Ventus Therapeutics Inc. has emerged with $60 million in series A funding and big ambitions to bring insights from structural biology to bear on two key aspects of innate immunity, inflammasome activation and cGAS-Sting signaling.
Biopharmas raising money in public or private financings, including: Aptose, Algernon, Delcath, Kura, Mind Medicine, Nascent, Oncology Venture, TG, Trillium.
Chronic obstructive pulmonary disease (COPD) is one of the most dangerous comorbidities for COVID-19 patients – as well as a major cause of death that predates the current pandemic. Pulmonx Corp. has the first minimally invasive valve to treat severe emphysema, which is a form of COPD that accounts for about one-quarter of the patients.
PERTH, Australia – Roughly 40% of Australia’s biotech companies are seeking capital as they feel the pinch from international travel bans that seriously hamper capital raising, according to a recent Ausbiotech survey.
RSS
